The global post-operative nausea and vomiting (PONV) market is expected to witness significant growth over the coming years, driven by the increasing number of surgical procedures, rising awareness regarding post-surgical complications, and advancements in anti-emetic therapies. PONV remains one of the most common complications experienced by patients following surgery and anesthesia, creating substantial demand for effective treatment and preventive medications.

According to industry analysis, the global post-operative nausea and vomiting market was valued at US$ 2.1 billion in 2022 and is projected to grow at a CAGR of 7.4% from 2023 to 2031, reaching approximately US$ 4.0 billion by the end of 2031. Growing healthcare expenditure, increasing adoption of minimally invasive surgeries, and rising focus on patient comfort and recovery are expected to support market expansion.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2969

Rising Number of Surgical Procedures Driving Market Growth

The increasing volume of surgical procedures performed worldwide is one of the primary factors fueling the growth of the PONV market. Surgical interventions related to orthopedics, oncology, gynecology, cardiovascular diseases, and gastrointestinal disorders are increasing significantly due to aging populations and the growing burden of chronic diseases.

Post-operative nausea and vomiting are common side effects associated with anesthesia and surgery, affecting patient recovery and extending hospital stays. As healthcare providers focus on improving post-operative care and patient satisfaction, the demand for advanced anti-emetic therapies is rising steadily.

Increasing Focus on Enhanced Recovery After Surgery (ERAS)

Healthcare systems worldwide are increasingly adopting Enhanced Recovery After Surgery (ERAS) protocols to improve patient outcomes and reduce hospitalization duration. Effective management of PONV is a critical component of these protocols, as uncontrolled nausea and vomiting can delay recovery and increase healthcare costs.

Hospitals and surgical centers are emphasizing preventive treatment strategies and combination therapies to minimize the occurrence of PONV. This trend is creating strong demand for innovative anti-emetic drugs and advanced drug delivery systems.

Advancements in Drug Formulations Supporting Innovation

Pharmaceutical companies are actively developing new formulations and delivery methods to improve the effectiveness of PONV treatments. Nasal sprays, intravenous formulations, and long-acting anti-emetic drugs are gaining popularity due to their faster onset of action and improved patient convenience.

The increasing use of serotonin antagonists, dopamine antagonists, corticosteroids, and neurokinin-1 receptor antagonists is enhancing treatment outcomes. Combination therapies are also becoming more common, particularly for high-risk surgical patients.

Technological advancements in drug delivery systems are expected to continue driving innovation in the market over the forecast period.

Growing Demand for Outpatient and Ambulatory Surgeries

The rising adoption of outpatient and ambulatory surgical procedures is another major factor contributing to market growth. Patients undergoing same-day surgeries require rapid recovery and effective management of post-operative symptoms to avoid hospital readmissions.

PONV management has become especially important in ambulatory surgical settings, where nausea and vomiting can significantly affect discharge timelines and patient satisfaction. This is encouraging healthcare providers to adopt preventive anti-emetic treatments more frequently.

👉 Discuss Implications for Your Industry or Do you want customize Report, Please Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2969

Competitive Landscape: Companies Focusing on New Product Development

The global PONV market is highly competitive, with both established pharmaceutical companies and emerging players investing in research, product innovation, and geographic expansion.

Key players operating in the market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, ANI Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, GlaxoSmithKline plc, and Merck & Co..

These companies are focusing on expanding their anti-emetic drug portfolios, strengthening distribution channels, and investing in clinical research to improve treatment efficacy and patient outcomes.

Recent Developments Strengthening the Market

Several strategic product approvals and launches are contributing to market expansion.

• In April 2022, Evoke Pharma, Inc. received new drug product exclusivity from the U.S. FDA for Gimoti (metoclopramide) nasal spray, strengthening its position in gastrointestinal and anti-emetic treatments.
• In February 2022, Acacia Pharma received U.S. FDA approval for Barhemsys, an intravenous formulation of amisulpride used to treat post-operative nausea and vomiting in patients who did not respond to previous anti-emetic therapies from different drug classes.
• Earlier, in September 2020, Sandoz, a division of Novartis AG, introduced generic Fosaprepitant, an anti-emetic drug designed to prevent chemotherapy-induced nausea and vomiting. The launch expanded access to cost-effective anti-emetic therapies globally.

Regional Outlook: North America Maintains Market Leadership

North America dominates the global PONV market due to advanced healthcare infrastructure, high surgical procedure volumes, and strong awareness regarding post-operative care. The presence of major pharmaceutical companies and favorable reimbursement policies are also supporting market growth in the region.

Europe represents another significant market, driven by increasing adoption of advanced anti-emetic therapies and rising focus on patient-centered surgical care.

Meanwhile, Asia Pacific is expected to witness the fastest growth during the forecast period due to improving healthcare infrastructure, increasing surgical procedures, and rising healthcare expenditure in countries such as China, India, and Japan.

Future Outlook: Personalized Treatment Strategies to Shape the Market

The future of the PONV market is expected to be influenced by personalized medicine, advanced combination therapies, and innovative drug delivery systems. Pharmaceutical companies are increasingly focusing on targeted therapies tailored to patient risk profiles and surgical procedures.

Growing emphasis on outpatient surgeries and enhanced recovery programs will continue to create demand for effective and fast-acting anti-emetic treatments. Companies investing in innovative formulations, strategic collaborations, and global market expansion are expected to strengthen their competitive positions.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=2969&ltype=S

In conclusion, the global post-operative nausea and vomiting market is poised for steady growth, reaching US$ 4.0 billion by 2031. Rising surgical procedure volumes, advancements in anti-emetic therapies, and increasing focus on patient recovery and comfort will continue to drive market development worldwide.

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453